Global CIS Insulin Market By Type (Rapid Acting, Long Acting, Short Acting, Intermediate Acting, and Premixed), By Application (Type I Diabetes and Type II Diabetes), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- account_circleAbout Me
- 1. Report Overview
- 2. Global CIS Insulin Market Scope:
- 3. Key Market Segments:
- 4. Market Dynamics:
- 5. Regional Analysis
- 6. Market Share & Key Players Analysis:
“The global CIS insulin market is expected to be worth around USD 593.62 million by 2032 from USD 466 million in 2022, growing at a CAGR of 2.45% during the forecast period 2021 to 2031.”
CIS insulin controls the metabolism of fats and carbohydrates by endorsing glucose absorption from the blood to fat tissue and skeletal muscles and affecting fat to store rather than use for energy. Produced by beta cells, insulin is the most significant peptide hormone in the pancreas. Insufficient production of insulin leads to sugar buildup in blood cells causing diabetes. The global market for CIS insulin is anticipated to boost due to leading factors, including a rising number of diabetes cases globally, eating habits of individuals, and varying lifestyles causing health disorders, including other metabolic diseases and obesity is anticipated to fuel the market growth.
Insulin is the body’s primary anabolic hormone produced in the pancreas by beta cells. It controls metabolism by promoting the preoccupation of glucose into the skeletal muscle cells, liver, and fat from the blood.
Global CIS Insulin Market Scope:
Based on the product global CIS Insulin market is classified into long-acting, rapid-acting, short-acting, premixed, and intermediate-acting. Rapid-acting CIS insulin accounts for the largest market share and is projected to register a CAGR of 2.4%. Rapid-acting insulin swaps the insulin usually produced by the human body—serving sugar in blood cells to other body tissues. Rapid-acting insulin works very fast to minimalize the increase in blood sugar post-eating, and its effect continues for hours. This type of insulin is frequently used to maintain blood glucose for longer. It is utilized to energy constrain the liver from creating more sugar, another factor making them an ideal choice amongst patients and physicians. These factors may boost the demand for the rapid-acting CIS insulin segment in 2023-2032.
Based on application, the market is divided into Type I Diabetes and Type II Diabetes segments.
The presence of a wide range of products in the Type II Diabetes segment and the high prevalence of Type II Diabetes supplements the growth of this market.
Among these, the type I segment registered a CAGR of 2.2% in 2022. The growing diagnosis degree of Type I helps boost the segment’s growth. People with type I diabetes use insulin to regulate their blood glucose levels. Around 10.2% of all diabetic patients have type I diabetes. It is anticipated that growing insulin production in advanced countries and several new products will boost the segment’s growth.
Key Market Segments:
- Rapid Acting
- Long Acting
- Short Acting
- Intermediate Acting
- Type I Diabetes
- Type II Diabetes
It is owing to the growing number of diabetes patients, eating habits of individuals, and changing lifestyles causing health disorders. Increasing government investments and initiatives to deliver a high-quality diagnosis, mainly across developed nations, including the US, China, and the UK, will create the CIS insulin market size in the upcoming ye. This includes obesity and other metabolic diseases, surging investments in R&D, innovations in insulin products, and a rise in CIS insulin application into type I and type II diabetes. Ars.
Despite optimistic growth projections, the global CIS insulin market is facing several problems that may somewhat hamper its growth. Some factors comprise the negative effect of the need for insulin therapy, such as pain and hypoglycemia at the site of injection, which may influence some individuals’ use. Other disadvantages, including electrolyte imbalance, weight gain, and in rare cases, decreased compliance, high nocturnal glucose levels, and peripheral hyperinsulinemia, also lower the development of the CIS insulin market. Growing insulin resistance, mainly amongst obese individuals, can restrain the market’s growth.
Geographically, North America holds 34.6% of the largest CIS insulin market share globally, followed by Europe and Asia. The high occurrence rate of metabolic diseases and diabetes, including obesity, is the main driver for the CIS insulin market. Moreover, constant R&D in this field for effective products would act as an assisting feature for market growth.
Asia-Pacific is detected to be a developing market for the CIS insulin market owing to the leading pharmaceutical companies selecting Asia-Pacific as the producing destination. Europe is the 2nd largest market due to comprehensive government initiatives regulating price and production acting as the feature for the insulin market growth. South American countries, including Mexico and Brazil, are the regions that have substantial potential for growth for insulin due to emerging medical infrastructure, a rise in population, and high disposable income. Furthermore, the increasing population in countries including India, China, etc., would consequence in the market development for the CIS insulin market.
Key Regions and Countries covered in the report:
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South America
- Rest of South AmerMENU
- South Africa
- Rest of MEA
legalBoehringer Ingelheim, Biocon, and several local companies produce biosimilars, including Farmak and Indrar. More than half of the market share is captured by local producers. The key players accept vital strategies, including geographical expansion, product development, mergers and acquisitions, and many other methods.
Major market players include…..
Market Key Players:
- Bristol-Myers Squibb
- Eli Lilly
- Boehringer Ingelheim
- Takeda Pharmaceuticals
- Merck KGaA
- Dongbao Enterprise Group Co. Ltd.
- Other key players
In June 2022- Lilly presented the new device of action data for further new analyses of Mounjaro™ (tirzepatide) injection for treating adults with type II diabetes at the 82nd Scientific Session of the American Diabetes Association’s®.
In November 2021 – Novo Nordisk publicized the acquisition of Dicerna Pharmaceuticals (Dicerna) to discover. Develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology.
In February 2022 — Novartis India Limited (NIL) announced an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories (Dr. Reddy’s) for a few of its Established Medicines, including the Voveran range, the Calcium range, and Methergine.
In January 2022- Bristol Myers Squibb and Century Therapeutics publicized a license and collaboration agreement to commercialize and develop up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“or T cell (“iT”) programs for hematologic malignancies and solid tumors.
For the CIS insulin market research study, the following years have been considered to estimate the market size:
Particular Scope Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Historic Year 2016 to 2020 Estimated Year 2022 Forecast Year 2023 to 2032
- account_circleAbout Me
Request a Sample ReportWe'll get back to you as quickly as possible
USD / per unit
USD / per unit
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|